WaveMan
WaveMan · Company
HTFL · Heartflow, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

HTFL Heartflow (HTFL) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001464521
Quote by TradingView
Form 144 · 22
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
141
13F, latest reported quarter
Conversions, 180 days
17
Codes C/M, not in net · $2.2M priced

What the filings say about HTFL

Insiders, 180 days
-$47.0M net sold
4 sellers · 62% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$30.7M
22 notices

Heartflow insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Heartflow, Inc. insiders sold a net $47.0M of stock across 39 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Rogers Campbell
Chief Medical Officer
SELL
2026-10-26 SECtraded 2026-10-22
23,933
$1.3M
n/a
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Sep 18, 2026.
  • The trade is 32.6% of the 73,453 shares held after it.
  • 1 other insider sold within 30 days.
  • 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Rogers Campbell sold about $1.3M of HTFL under a 10b5-1 plan on Oct 22, 2026; 1 other insider sold within 30 days and 141 funds added in the latest 13F quarter.
Farquhar John C.M.
Chief Executive Officer
SELL
2026-10-14 SECtraded 2026-10-12
38,900
$1.9M
+11.4%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Sep 11, 2026.
  • The trade is 13.7% of the 283,014 shares held after it.
  • 2 other insiders sold within 30 days.
  • 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Farquhar John C.M. sold about $1.9M of HTFL under a 10b5-1 plan on Oct 12, 2026; 2 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.
Verghese Vikram
Chief Financial Officer
SELL
2026-09-18 SEC
16,766
$850.9K
+12.7%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Sep 17, 2026.
  • The trade is 10.8% of the 155,183 shares held after it.
  • 2 other insiders sold within 30 days.
  • 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Verghese Vikram sold about $850.9K of HTFL under a 10b5-1 plan on Sep 18, 2026; 2 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.
Rogers Campbell
Chief Medical Officer
SELL
2026-09-21 SECtraded 2026-09-18
19,682
$987.1K
+13.0%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Aug 17, 2026.
  • The trade is 24.6% of the 79,956 shares held after it.
  • 2 other insiders sold within 30 days.
  • 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Rogers Campbell sold about $987.1K of HTFL under a 10b5-1 plan on Sep 18, 2026; 2 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.
Verghese Vikram
Chief Financial Officer
SELL
2026-09-18 SECtraded 2026-09-17
7,579
$379.8K
+12.7%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Sep 15, 2026.
  • The trade is 4.4% of the 171,949 shares held after it.
  • 2 other insiders sold within 30 days.
  • 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Verghese Vikram sold about $379.8K of HTFL under a 10b5-1 plan on Sep 17, 2026; 2 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.
39 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 34 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$47.0M over 180 days
-$15.5M over 90 days · -$27.7M of it by a 10%+ holder
below 97% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
141 funds bought in last quarter
more than 72% of Medical Devices
Revenue
+39.9% year over year
more than 85% of Medical Devices
Margin
-66.3% net margin
below 72% of Medical Devices
Buybacks
no share repurchases reported
Short interest
10.1% of the float short (float per yahoo 2026-10-26) · 3.3 days to cover · settled 2026-09-30
more than 81% of Medical Devices
What changed in the last 30 days
Oct 26Chief Medical Officer Rogers Campbell sold $1.3M under a 10b5-1 plan (Oct 22)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 22Officer Rogers Campbell filed to sell $1.3M by Oct 22 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 22Member of immediate family of any of the foregoing Rogers Campbell filed to sell $311.0K by Oct 22 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 14Chief Executive Officer Farquhar John C.M. sold $1.9M under a 10b5-1 plan (Oct 12)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 13Officer Farquhar John C.M. filed to sell $1.9M by Oct 12 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch HTFL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+44.3%12M
-48%-17%+14%+44%2025-102025-122026-022026-042026-062026-082026-10 2026-02-04 · Bain Capital Life Sciences Investors, LLC sold $56.1M2026-04-30 · Bain Capital Life Sciences III General Partner, LLC sold $26.0M2026-04-29 · Bain Capital Life Sciences III General Partner, LLC sold $23.4M2026-04-28 · Bain Capital Life Sciences III General Partner, LLC sold $7.8M2026-10-12 · Farquhar John C.M. sold $1.9M2026-04-30 · Bain Capital Life Sciences III General Partner, LLC sold $1.7M2026-03-19 · Rogers Campbell sold $1.7M2026-09-10 · Farquhar John C.M. sold $1.6M2026-02-12 · Rogers Campbell sold $1.6M2026-04-01 · Rogers Campbell sold $1.6M2026-09-11 · Verghese Vikram sold $1.5M2026-08-18 · Farquhar John C.M. sold $1.5M2026-09-03 · Verghese Vikram sold $1.4M2026-06-24 · Farquhar John C.M. sold $1.4M2026-08-21 · Farquhar John C.M. sold $1.4M2026-10-22 · Rogers Campbell sold $1.3M2025-12-16 · Lightcap Jeffrey C bought $1.1M2026-09-18 · Rogers Campbell sold $987.1K2026-09-18 · Verghese Vikram sold $850.9K2026-05-11 · Farquhar John C.M. sold $657.0K2026-06-10 · Farquhar John C.M. sold $643.0K2026-08-10 · Farquhar John C.M. sold $638.7K2026-07-10 · Farquhar John C.M. sold $626.1K2026-02-10 · Farquhar John C.M. sold $619.6K2026-08-14 · Farquhar John C.M. sold $607.8K2026-04-10 · Farquhar John C.M. sold $602.9K2026-08-17 · Rogers Campbell sold $380.1K2026-09-17 · Verghese Vikram sold $379.8K2026-09-08 · Verghese Vikram sold $332.2K2026-09-02 · Verghese Vikram sold $297.3K2026-03-10 · Farquhar John C.M. sold $290.9K2026-05-18 · Rogers Campbell sold $261.3K2026-03-18 · Farquhar John C.M. sold $243.1K2026-07-15 · Rogers Campbell sold $237.1K2026-09-14 · Verghese Vikram sold $230.7K2026-03-05 · Cullivan Julie A sold $228.1K2026-02-05 · Cullivan Julie A sold $218.6K2026-09-11 · Farquhar John C.M. sold $194.5K2026-09-15 · Verghese Vikram sold $33.4K2026-10-22 · Rogers Campbell filed to sell $311.0K2026-10-22 · Rogers Campbell filed to sell $1.3M2026-10-13 · Farquhar John C.M. filed to sell $1.9M2026-09-18 · Rogers Campbell filed to sell $987.1K2026-09-18 · Rogers Campbell filed to sell $283.5K2026-09-18 · Verghese Vikram filed to sell $850.9K2026-09-17 · Verghese Vikram filed to sell $379.8K2026-09-15 · Verghese Vikram filed to sell $33.4K2026-09-14 · Verghese Vikram filed to sell $230.7K2026-09-11 · Farquhar John C.M. filed to sell $194.5K2026-09-11 · Verghese Vikram filed to sell $1.5M2026-09-10 · Farquhar John C.M. filed to sell $1.6M2026-09-08 · Verghese Vikram filed to sell $332.2K2026-09-03 · Verghese Vikram filed to sell $1.4M2026-09-02 · Verghese Vikram filed to sell $297.3K2026-08-21 · Farquhar John C.M. filed to sell $1.4M2026-08-18 · Farquhar John C.M. filed to sell $1.5M2026-08-17 · Rogers Campbell filed to sell $380.1K2026-08-14 · Cohen Arthur Bruce filed to sell $8.4M2026-08-14 · Farquhar John C.M. filed to sell $607.8K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns HTFL: institutional holders (13F)

13F holdings, latest reported quarter
Bain Capital Life Sciences Investors, LLC
8,448,158 sh
$247.9M
WELLINGTON MANAGEMENT GROUP LLP
7,864,226 sh
$230.7M
BlackRock, Inc.
5,197,747 sh
$152.5M
FMR LLC
4,820,944 sh
$141.4M
VANGUARD PORTFOLIO MANAGEMENT LLC
3,584,428 sh
$105.2M

Congress trades in HTFL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

HTFL planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Rogers Campbell
Filed 2026-10-22
$311.0K
Rogers Campbell
Filed 2026-10-22
$1.3M
Farquhar John C.M.
Filed 2026-10-13
$1.9M
Rogers Campbell
Filed 2026-09-18
$987.1K
Rogers Campbell
Filed 2026-09-18
$283.5K

HTFL mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
BARON DISCOVERY FUND
$47.1M position · as of 2026-06-30
2.6%
Global X HealthTech ETF
$498.8K position · as of 2026-05-31
2.0%
Fidelity Disruptive Medicine ETF
$774.3K position · as of 2026-05-31
1.9%
Nuveen Small Cap Growth Opportunities Fund
$3.5M position · as of 2026-07-31
1.3%
ALGER SMALL CAP FOCUS FUND
$11.1M position · as of 2026-07-31
1.3%
Baron Health Care Fund
$1.4M position · as of 2026-06-30
1.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $47.0M sold by insiders over 180 days, 141 funds added last quarter, $30.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

HTFL financials

Revenue growth
+39.9%
XBRL, annual
Net margin
-66.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$212.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-55.8%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$59.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.24x
long-term debt only, 2025-06-30 (12 months older than the period end); equity 2026-06-30
Cash flow to debt
-0.76x
TTM operating cash flow over long-term debt only, 2025-06-30 (12 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
-47.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-37.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$5.0B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term debt only, 2025-06-30 (12 months older than the period end), minus cash 2026-06-30
FCF yield
-1.2%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$176.0M$125.8M$87.2M
Gross profit$135.2M$94.4M$58.1M
Operating income-$64.1M-$61.2M-$72.9M
Net income-$116.8M-$96.4M-$95.7M
EPS (diluted)-3.17-17.98-25.32
Operating cash flow-$54.0M-$69.0M-$76.4M
Cash$44.8M$51.4M$122.8M
Long-term debtn/a$0n/a
Buybacksn/an/a$228.0K
SEC XBRL, fiscal years, as known on 2026-10-27

HTFL Stock Sonar score 6/7 axes

Find similar shapesCompare

HTFL ranks highest on growth (85th percentile) and institutional and government (72nd), and lowest on insider conviction (2nd), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
34
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-47.0% · 31 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-37.6% · 36 pct, sector of 188
Financial health
46
Inputs
  • Debt to equity0.24x · 56 pct, sector of 159
  • Cash flow to debt-0.76x · 36 pct, sector of 150
Growth
85
Inputs
  • Revenue growth, YoY+39.9% · 85 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
2
Inputs
  • Net Form 4 buying (codes P and S), 180d-$32.8M · 4 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
72
Inputs
  • Funds adding, latest quarter141 · 72 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$750K · 71 pct, sector of 50
Risk and compliance
59
Inputs
  • Short interest, % of float+10.1% · 18 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

HTFL filings, in plain words

Are Heartflow insiders buying or selling HTFL?

In the 180 days to 2026-10-27, Heartflow insiders were net sellers, a net $47.0M across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of HTFL?

Yes. 22 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $30.7M of stock; the latest, by Rogers Campbell, was filed 2026-10-22.

Read the full summary

In the 180 days to 2026-10-27, Heartflow insiders were net sellers of HTFL, a net $47.0M across purchases and sales reported on Form 4 by 4 sellers. Most of that figure, $27.7M, came from a holder of 10% or more rather than an officer or director. 62% of the 26 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 22 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $30.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies